0001562180-21-000931.txt : 20210205
0001562180-21-000931.hdr.sgml : 20210205
20210205162127
ACCESSION NUMBER: 0001562180-21-000931
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210203
FILED AS OF DATE: 20210205
DATE AS OF CHANGE: 20210205
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Meyers Michael L.
CENTRAL INDEX KEY: 0001664204
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37708
FILM NUMBER: 21595685
MAIL ADDRESS:
STREET 1: C/O SYNDAX PHARMACEUTICALS, INC.
STREET 2: 400 TOTTEN POND ROAD, SUITE 110
CITY: WALTHAM
STATE: MA
ZIP: 02451
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Syndax Pharmaceuticals Inc
CENTRAL INDEX KEY: 0001395937
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 320162505
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 35 GATEHOUSE DRIVE
STREET 2: BUILDING D, FLOOR 3
CITY: WALTHAM
STATE: MA
ZIP: 02451
BUSINESS PHONE: 781-419-1400
MAIL ADDRESS:
STREET 1: 35 GATEHOUSE DRIVE
STREET 2: BUILDING D, FLOOR 3
CITY: WALTHAM
STATE: MA
ZIP: 02451
4
1
primarydocument.xml
PRIMARY DOCUMENT
X0306
4
2021-02-03
false
0001395937
Syndax Pharmaceuticals Inc
SNDX
0001664204
Meyers Michael L.
C/O SYNDAX PHARMACEUTICALS, INC.
35 GATEHOUSE DRIVE, BUILDING D, FLOOR 3
WALTHAM
MA
02451
false
true
false
false
SVP, Chief Medical Officer
Common Stock
2020-07-31
4
J
false
2665.00
7.97
A
13395.00
D
Common Stock
2021-01-31
4
J
false
1771.00
12.00
A
15166.00
D
Stock Option (Right to Buy)
21.36
2021-02-03
4
A
false
80000.00
0.00
A
2031-02-03
Common Stock
80000.00
80000.00
D
The Reporting Person is voluntarily filing this Form 4 to report the acquisition of 2,665 shares by the Reporting Person on 07/31/2020 pursuant to the Issuer's Employee Stock Purchase Plan.
The Reporting Person is voluntarily filing this Form 4 to report the acquisition of 1,771 shares by the Reporting Person on 01/31/2021 pursuant to the Issuer's Employee Stock Purchase Plan.
1/48th of the shares subject to the option shall vest monthly over a four-year period.
/s/ Michael A. Metzger, Attorney-in-Fact
2021-02-05